trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast']
a game-changer in breast cancer and a major win for antibody-drug conjugate class of drugs. her2-targeting trastuzumab deruxtecan better than chemotherapy in previously treated her2-low(!) advanced breast cancer #asco22 
Director, Englander Institute for Precision Medicine @WCMenglanderIPM, Associate Director @wcmc_ctsc & ICB, Co-Founder @volastratx & @onethreebiotech